PARTNER 3 Trial Summary: Mack MJ et al. randomized 1000 patients (mean age, 73 years), male population (69.3%), with lower STS-PROM scores (mean 1.9%) and fewer comorbidities (low-risk surgical candidates) to either TAVR with balloon-expanded valve or surgery. The primary objective was to compare outcomes with TAVR vs. surgical AV replacement in patients with severe..
CARRESS HF Trial Summary: Bart et al. randomized 188 patients with decompensated acute heart failure and worsening renal function (Increase in serum creatinine ≥0.3 mg/dL) – [cardiorenal syndrome] to ultrafiltration (fluid removal of 200 mL/hr, n=94) or medical therapy (Protocol driven IV diuresis, n=94). The primary objective was to assess if ultrafiltration improves volume removal,..
BRIDGE Trial Summary: Douketis JD et al. randomized 1,884 patients on warfarin (INR 2-3 for ≥3m) with AF or A-flutter and CHADS2 Score ≥1 to LMWH: dalteparin (100 IU/kg BID) or placebo. The objective was to assess if bridging anticoagulation reduce rates of arterial thromboembolism compared to no bridging in patients with atrial fibrillation undergoing..
VALIANT Trial Summary: Pfeffer et al. randomized 14,703 patients with acute MI within prior 10 days complicated by HF and/or LVEF ≤35% to either valsartan or captopril or combination of both. The objective was to assess the efficacy of ARBs compared with ACE-I in patients in the post-MI period complicated by HF and/or LV systolic dysfunction…
COMMANDER HF Trial Summary: Zannand F et al. randomized 5,022 patients with coronary artery disease and heart failure to undergo treatment with either rivaroxaban or a placebo. The primary objective of the study was to assess if rivaroxaban could reduce thrombin production and improve outcomes in patients with CAD and HF. The results showed that rivaroxaban..
TRED-HF Trial Summary: Halliday et al. randomized 51 patients with dilated cardiomyopathy (LVEF<40%) who recovered with the improvement of symptoms to either continual treatment with HF medications or withdrawal of HF therapy. The objective was to assess the safety of withdrawing treatment in patients with dilated cardiomyopathy whose symptoms and cardiac function have recovered. The results showed significant replase..